Motif Bio plc (LON:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will participate in the following event:
Cantor Antibiotics Summit
January 17, 2018
Omni Berkshire Hotel
New York, NY USA
Graham Lumsden, Chief Executive Officer, will participate in a panel discussion, “Catalysts to Look for in 2018.”
The Cantor Antibiotics Summit will bring together leading antibiotic companies to discuss: what will drive the uptake of these new products, novel ways to treat infections and important catalysts to look forward to in 2018. The Summit will consist of various panels, in addition to one-on-one and small group meetings.
Motif Bio plc is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria, including MRSA. The Company’s lead product candidate, iclaprim, is being developed for high-risk MRSA patient populations. The first proposed indication, and near-term commercial opportunity, is for the treatment of ABSSSI, one of the most common bacterial infections, with 3.6 million patients hospitalised annually in the U.S. The Company believes that iclaprim may be suitable for first-line empiric therapy in ABSSSI patients, especially those with renal impairment, with or without diabetes. Unlike current standard of care antibiotics, in clinical trials to date, nephrotoxicity has not been observed with iclaprim and dosage adjustment has not been required in patients with renal impairment.
